Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof

US10875903B2 · kind B2 · utility

Assignee

• CHINA PHARMACEUTICAL UNIVERSITY · CN

Inventors

• Shuzhen WANG · Nanjing, CN
• Yijun Chen · Madison, US
• Dongyang He · Nanjing, CN
• Nan Liu · Nanjing, CN
• Chao Ma · Jinan, CN
• Zhenyue Gao · Nanjing, CN

Key dates

• Filing date: May 5, 2014
• Grant date: Dec 29, 2020
• Expiry date: Mar 14, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions are provided. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.